natgillin/translations-raw huggingface dataset:
Metformin must be discontinuedat the time of surgery under general, spinal or epidural anaesthesia.
Uporabo metformina je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
Since this product has been marketed, the following side effects have also been reported:
Odkar je zdravilo na trgu, so poročali tudi o naslednjem neželenem učinku
You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse.
Priporočamo vam, da se držite navodil za nego kože in stopal, kot vam jih priporoča vaš zdravnik ali medicinska sestra.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC ODGOVOREN ZA SPROŠČANJE SERIJ
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX)
VMESNA ŠKATLA PRI SKUPNEM PAKIRANJU (BREZ "BLUE BOX" PODATKOV)
During treatment with Zomarist, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or have worsening renal function.
Med zdravljenjem z zdravilom Zomarist bo zdravnik vsaj enkrat letno preveril delovanje ledvic, če pa ste starejša oseba in/ali se vam delovanje ledvic slabša, pa še pogosteje.
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.
Po peroralnem odmerjanju je neabsorbirani delež v blatu znašal 20-30 %.
Continue to follow any advice about diet that your doctor has given you.
Še naprej se držite diete, ki vam jo je priporočil zdravnik.
Your doctor may prescribe this medicine alone or with certain other medicines that lower the level of sugar in your blood.
Zdravnik vam lahko predpiše, da jemljete to zdravilo samostojno ali pa skupaj z določenimi drugimi zdravili, ki znižujejo raven sladkorja v krvi.
All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product.
Vsi simptomi in nenormalni laboratorijski izvidi so izzveneli brez zdravljenja po prekinitvi jemanja preiskovanega zdravila.
Other medicines and Zomarist
Druga zdravila in zdravilo Zomarist
The safety and efficacy of Zomarist in children and adolescents (< 18 years) have not been established.
Varnost in učinkovitost zdravila Zomarist pri otrocih in mladostnikih (< 18 let) nista bili dokazani.
The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the longterm benefit of intensive blood glucose control in type 2 diabetes.
V prospektivni randomizirani študiji UKPDS (UK Prospective Diabetes Study - Britanska prospektivna študija diabetesa) so ugotovili dolgoročno koristnost intenzivnega uravnavanja koncentracije glukoze pri diabetesu tipa 2.
Your doctor will tell you exactly the dose of Zomarist to take.
Zdravnik vam bo natančno povedal, kolikšen odmerek zdravila Zomarist morate jemati.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment.
Bolnik mora biti o tem poučen, koncentracijo glukoze v krvi pa je treba meriti pogosteje, še posebno na začetku zdravljenja.
Therefore, vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.
Zato ni verjetno, da bi vildagliptin vplival na presnovni očistek sočasno uporabljanih zdravil, ki se presnavljajo z encimi CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 ali CYP 3A4/5.
Do not stop taking Zomarist unless your doctor tells you to.
Ne prenehajte jemati zdravila Zomarist, če vam tega ne naroči zdravnik.
Three other subjects experienced oedema of the feet, with paraesthesia in two cases.
Pri treh drugih osebah je prišlo do otekanja stopal, v dveh primerih s parestezijo.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 µg/ml, even at maximum doses.
V kontroliranih kliničnih preskušanjih najvišje koncentracije metformina v plazmi (Cmax) niso presegale 4 µg/ml niti pri najvišjih odmerkih.
In vitro studies demonstrated that vildagliptin does not inhibit/induce CYP 450 enzymes.
In vitro študije so pokazale, da vildagliptin ne zavira/inducira encimov CYP 450.
Diagnostic laboratory findings are decreased blood pH (< 7.35), increased plasma lactate levels (> 5 mmol/l) and an increased anion gap and lactate/pyruvate ratio.
Diagnostični laboratorijski izvidi so zmanjšan pH krvi (< 7,35), zvišane ravni laktata v plazmi (> 5 mmol/l) in povečana anionska vrzel ter razmerje laktat/piruvat.
Findings were only observed in association with maternal toxicity at ≥ 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.
Učinke so opažali samo v povezavi s toksičnostjo za mater pri odmerkih ≥ 150 mg/kg, vključevali pa so prehodno zmanjšanje telesne mase in zmanjšano motorično aktivnost v F1 generaciji.
The following statements reflect the information available on the individual active substances.
Naslednje trditve odražajo podatke, ki so na voljo za obe posamezni zdravilni učinkovini.
Glucocorticoids, beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
Glukokortikoidi, beta-2 agonisti in diuretiki imajo intrinzično hiperglikemično aktivnost.
It is assumed that the pharmacokinetics of metformin absorption are non-linear.
Domnevajo, da je farmakokinetika absorpcije metformina nelinearna.
Sulphonylureas are known to cause hypoglycaemia.
Znano je, da sulfoniluree povzročajo hipoglikemijo.
Information on the likely symptoms of overdose with vildagliptin was taken from a rising dose tolerability study in healthy subjects given vildagliptin for 10 days.
Podatki o verjetnih simptomih prevelikega odmerjanja vildagliptina temeljijo na študiji prenašanja naraščajočih odmerkov, izvedeni na zdravih osebah, ki so prejemale vildagliptin 10 dni.
Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.
Ker vildagliptin ni niti substrat encimov citokroma P (CYP) 450 niti ne zavira ali inducira encimov CYP 450, ni verjetno, da bi prišlo do interakcij z učinkovinami, ki so substrati, zaviralci ali induktorji teh encimov.
No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose.
Povezave med neželenimi učinki in starostjo, etnično pripadnostjo, trajanjem zdravljenja ali velikostjo dnevnega odmerka niso ugotovili.
Taking Zomarist with or just after food may reduce gastrointestinal symptoms associated with metformin (see also section 5.2).
Jemanje zdravila Zomarist s hrano ali takoj po njej lahko ublaži gastrointestinalne simptome, ki so povezani z jemanjem metformina (glejte tudi poglavje 5.2).
Combination with a sulphonylurea
Kombinacija s sulfonilureo
OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX)
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA (VKLJUČNO Z "BLUE BOX" PODATKI)
These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.
Ta zvišanja vrednosti aminotransferaz so bila večinoma asimptomatska, neprogresivne narave in niso bila povezana s holestazo ali z ikterusom.
Should these occur, you should promptly consult your doctor.
Če pride do teh sprememb, takoj obvestite svojega zdravnika.
Diabetic skin lesions are a common complication of diabetes.
Diabetične spremembe na koži so pogost diabetični zaplet.
A study in healthy volunteers showed that cimetidine, administered as 400 mg twice daily, increased metformin systemic exposure (AUC) by 50%.
V študiji na zdravih prostovoljcih se je pokazalo, da je uporaba cimetidina v odmerku 400 mg dvakrat na dan povečala sistemsko izpostavljenost metforminu (AUC) za 50 %.
You may need more frequent blood glucose and kidney function tests or your doctor may need to adjust the dosage of Zomarist.
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Zomarist.
The following data are findings from studies performed with vildagliptin or metformin individually.
Naslednji podatki so izsledki študij, ki so jih izvajali ločeno z vildagliptinom ali metforminom.
No new toxicities associated with the combination were identified.
Pri tem niso ugotovili nobenega novega toksičnega vpliva, povezanega s kombinacijo učinkovin.
Biotransformation Metformin is excreted unchanged in the urine.
Biotransformacija Metformin se izloča z urinom v nespremenjeni obliki.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD08
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD08
10 film-coated tablets 30 film-coated tablets 60 film-coated tablets 120 film-coated tablets 180 film-coated tablets 360 film-coated tablets
10 filmsko obloženih tablet 30 filmsko obloženih tablet 60 filmsko obloženih tablet 120 filmsko obloženih tablet 180 filmsko obloženih tablet 360 filmsko obloženih tablet
Zomarist is not a substitute for insulin in insulin-requiring patients and should not be used in patients with type 1 diabetes.
Zdravilo Zomarist ne more nadomestiti zdravljenja z insulinom pri bolnikih, ki potrebujejo insulin, in se ga ne sme uporabljati pri bolnikih z diabetesom tipa 1.
The mean volume of distribution of vildagliptin at steady-state after intravenous administration (Vss) is 71 litres, suggesting extravascular distribution.
Povprečen volumen porazdelitve vildagliptina v stanju dinamičnega ravnovesja po intravenski aplikaciji (Vss) je 71 litrov, kar kaže ne ekstravaskularno porazdelitev.
- Do not use Zomarist if you are pregnant or breast-feeding (see also “Do not take Zomarist”).
- Če ste noseči ali dojite, ne smete uporabljati zdravila Zomarist (glejte tudi “Ne jemljite zdravila Zomarist”).
Your doctor will test your blood and urine for sugar regularly.
Poleg tega vam bo zdravnik redno pregledoval vsebnost sladkorja v krvi in urinu.
Renal clearance of metformin is > 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Ledvični očistek metformina je > 400 ml/min, kar nakazuje, da se metformin izloča z glomerulno filtracijo in tubulno sekrecijo.
The Cmax for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.
Cmax vildagliptina in površina pod krivuljo časovne porazdelitve koncentracij v plazmi (AUC) sta se v okviru terapevtskih odmerkov povečevali približno sorazmerno z velikostjo odmerka.
Zomarist may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly.
Zdravilo Zomarist lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
This medicine has been shown to reduce blood sugar, which may help to prevent complications from your diabetes.
Dokazano je bilo, da to zdravilo znižuje koncentracijo sladkorja v krvi in tako pomaga preprečevati zaplete sladkorne bolezni.
If you take too many Zomarist tablets, or if someone else takes your tablets, talk to a doctor or pharmacist immediately.
Če ste vzeli večji odmerek zdravila Zomarist, kot bi smeli Če ste vzeli preveč tablet zdravila Zomarist ali če kdo drug vzame vaše tablete, se takoj obrnite na zdravnika ali farmacevta.
60 film-coated tablets.
60 filmsko obloženih tablet.
Renal impairment: In subjects with mild, moderate, or severe renal impairment, systemic exposure to vildagliptin was increased (Cmax 8-66%; AUC 32-134%) and total body clearance was reduced compared to subjects with normal renal function.
Okvara ledvic: Pri bolnikih z blago, zmerno ali hudo okvaro ledvic je bila izpostavljenost vildagliptinu večja (Cmax 8-66 %; AUC 32-134 %), celotni telesni očistek pa je bil manjši v primerjavi z osebami z normalnim delovanjem ledvic.
However, vildagliptin cannot be removed by haemodialysis, although the major hydrolysis metabolite (LAY 151) can.
Vendar pa vildagliptina ni mogoče odstraniti s hemodializo, je pa mogoče s hemodializo odstraniti njegov glavni presnovek (LAY 151).
Vildagliptin Information regarding overdose with vildagliptin is limited.
Podatki o prevelikem odmerjanju vildagliptina so omejeni.
Studies in animals have shown excretion of both metformin and vildagliptin in milk.
Študije na živalih kažejo na izločanje metformina in vildagliptina v mleko.
If you have reduced kidney function, your doctor may prescribe a lower dose.
Če imate zmanjšano delovanje ledvic, vam bo zdravnik morda predpisal nižji odmerek.
If you forget to take Zomarist
Če ste pozabili vzeti zdravilo Zomarist
You should stop taking Zomarist and see your doctor immediately if you experience the following side effects:
Prenehajte jemati zdravilo Zomarist in takoj obiščite zdravnika, če se pri vas pojavijo naslednji neželeni učinki:
- Do not store above 30C.
- Shranjujte pri temperaturi do 30 C.
Following administration of a dose of 850 mg, the plasma peak concentration was 40% lower, AUC was decreased by 25% and time to peak plasma concentration was prolonged by 35 minutes.
Po aplikaciji odmerka 850 mg je bila najvišja koncentracija v plazmi 40 % nižja, AUC manjša za 25 %, čas do najvišje koncentracije v plazmi pa daljši za 35 minut.
The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species, and the high systemic exposure ratios at which tumours were observed.
Ocenjeno je, da zvišana incidenca teh tumorjev pri miših ne predstavlja pomembnega tveganja za ljudi glede na to, da vildagliptin in njegov glavni presnovek nista genotoksična, da je do tumorjev prišlo le pri eni živalski vrsti in glede na visoka razmerja med izpostavljenostmi, pri katerih so tumorje opažali.
Another two-year carcinogenicity study was conducted in mice at oral doses up to 1000 mg/kg.
Drugo dvoletno študijo karcinogenosti so opravili na miših s peroralnimi odmerki do 1.000 mg/kg.
Embryofoetal toxicity was evaluated in rats and rabbits.
Toksičnost za zarodek in plod so ocenjevali pri podganah in kuncih.
Both active substances, vildagliptin and metformin, help to control the level of sugar in the blood.
Obe učinkovini, vildagliptin in metformin, pomagata uravnavati koncentracijo sladkorja v krvi.
**Isolated cases of liver function test abnormalities or hepatitis resolving upon metformin discontinuation have been reported.
**Poročali so o posameznih primerih nenormalnih vrednosti jetrnih testov ali hepatitisa, ki so izzveneli po ukinitvi metformina.
Driving and using machines If you feel dizzy while taking Zomarist, do not drive or use any tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Če ste med jemanjem zdravila Zomarist omotični, ne vozite avtomobila in ne upravljajte z orodji in stroji.
Vildagliptin has a low potential for interactions with co-administered medicinal products.
Vildagliptin ima le majhno možnost medsebojnega delovanja z drugimi sočasno uporabljenimi zdravili.
Stop taking Zomarist for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal.
Za kratek čas prenehajte jemati zdravilo Zomarist, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions.
Poleg tega so v obdobju trženja zdravila poročali o mehurčastih in eksfoliacijskih kožnih spremembah.
It is unknown whether vildagliptin is excreted in human milk, but metformin is excreted in human milk in low amounts.
Ni znano, ali se vildagliptin izloča v materino mleko, se pa v materino mleko v majhnih količinah izloča metformin.
At the usual metformin doses and dosing schedules, steady state plasma concentrations are reached within 24-48 h and are generally less than 1 µg/ml.
Pri običajnih odmerkih in shemah odmerjanja se plazemske koncentracije v stanju dinamičnega ravnovesja dosežejo v 24-48 urah, večinoma pa so nižje od 1 µg/ml.
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Zomarist before or at the time of the injection.
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Zomarist.
At study endpoint (2 years), the HbA1c was similar to baseline values in both treatment groups and the body weight changes and hypoglycaemia differences were maintained.
Po določenem času v študiji (po 2 letih) je bila v obeh skupinah vrednost HbA1c podobna izhodiščni, medtem ko je telesna masa ostala spremenjena, obdržale pa so se tudi spremembe glede hipoglikemij.
Hydroxypropylcellulose Magnesium stearate
Jedro tablete hidroksipropilceluloza magnezijev stearat
Table 5 Adverse reactions for metformin component
Preglednica 5 Neželeni učinki metformina
In case of dehydration (severe diarrhoea or vomiting, fever, or reduced fluid intake), metformin should be temporarily discontinued and contact with a healthcare professional is recommended.
V primeru dehidracije (huda driska ali bruhanje, zvišana telesna temperatura ali zmanjšan vnos tekočine) je treba jemanje metformina začasno prekiniti; priporoča se posvet z zdravstvenim delavcem.
Children and adolescents The use of Zomarist in children and adolescents up to 18 years of age is not recommended.
Otroci in mladostniki Pri otrocih in mladostnikih do 18. leta starosti uporaba zdravila Zomarist ni priporočena.
Metformin is contraindicated in patients with GFR <30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3).
Metformin je kontraindiciran pri bolnikih z GFR< 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic (glejte poglavje 4.3).
Stop taking Zomarist and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.
Takoj prenehajte jemati zdravilo Zomarist in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the amide hydrolysis product (4% of dose).
Glavni presnovek (LAY 151) nima farmakološkega učinka in nastane s hidrolizo ciano skupine ter predstavlja 57 % odmerka, sledi pa mu produkt hidrolize amida (4 % odmerka).
Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications.
V kliničnih preskušanjih niso opažali zvišane incidence kožnih sprememb, vendar je pri bolnikih s kožnimi obolenji kot diabetičnim zapletom obseg izkušenj omejen.
Both insulin and glucagon are made in the pancreas.
Tako insulin kot glukagon nastajata v trebušni slinavki.
It can also develop if the body produces too much glucagon.
Diabetes se razvije tudi v primeru, ko organizem tvori preveč glukagona.
Adverse reactions listed in Table 5 are based on information available from the metformin Summary of Product Characteristics available in the EU.
Neželeni učinki, ki so navedeni v preglednici 5, temeljijo na podatkih iz Povzetka glavnih značilnosti zdravila, ki se za metformin uporablja v Evropski skupnosti.
Continue to take this medicine as long as your doctor prescribes it so that it can continue to control your blood sugar.
Z jemanjem zdravila nadaljujte, dokler vam ga zdravnik predpisuje, tako da boste lahko v tem času z zdravilom uravnavali raven sladkorja v krvi.
Administration of vildagliptin with food resulted in a decreased Cmax (19%) compared to dosing in the fasting state.
Zaradi uživanja vildagliptina skupaj s hrano se je znižala Cmax (19 %) v primerjavi z odmerjanjem na tešče.
Zomarist should not be used during pregnancy.
Zdravila Zomarist ne smete uporabljati pri nosečnicah.
Assessment of each individual MACE component showed no increased risk (similar M-H RR).
Pri ocenjevanju posameznih kategorij pomembnih neželenih kardiovaskularnih dogodkov pri nobeni niso odkrili povečanja tveganja (razmerje M-H RR je bilo podobno).
Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose.
Glavna pot izločanja vildagliptina pri človeku je njegova presnova, ki odstrani 69 % odmerka.
Animal studies of up to 13-week duration have been conducted with the combined substances in Zomarist.
Na živalih so opravili 13 tednov trajajoče študije s kombinacijo učinkovin v zdravilu Zomarist.
If this happens you must stop taking Zomarist and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.
V tem primeru morate prenehati jemati zdravilo Zomarist in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo;
A large overdose of metformin (or co-existing risk of lactic acidosis) may lead to lactic acidosis, which is a medical emergency and must be treated in hospital.
Zaradi znatno prevelikega odmerjanja metformina (ali sočasnega tveganja za laktacidozo) lahko pride do laktacidoze, ki je urgentno stanje in zahteva bolnišnično zdravljenje.
- The other ingredients are: Hydroxypropylcellulose, magnesium stearate, hypromellose, titanium dioxide (E 171), yellow iron oxide (E 172), macrogol 4000 and talc.
- Druge sestavine zdravila so: hidroksipropilceluloza, magnezijev stearat, hipromeloza, titanov dioksid (E 171), rumeni železov oksid (E 172), makrogol 4000 in smukec.
Vildagliptin, a member of the islet enhancer class, is a potent and selective dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Vildagliptin iz skupine spodbujevalcev Langerhansovih otočkov je močan in selektiven zaviralec dipeptidil peptidaze 4 (DPP-4).
• Liver disease (hepatitis) (rare): Symptoms include yellow skin and eyes, nausea, loss of appetite or dark-coloured urine, which may indicate liver disease (hepatitis).
• bolezen jeter (hepatitis) (redek): simptomi vključujejo rumena koža in oči, slabost, izguba apetita ali temno obarvan urin, kar lahko kaže na bolezen jeter (hepatitis) ;
If you stop taking Zomarist
Če ste prenehali jemati zdravilo Zomarist
Avoid excessive alcohol intake while taking Zomarist since this may increase the risk of lactic acidosis (please see section “Warnings and precautions”).
Med jemanjem zdravila Zomarist ne uživajte čezmernih količin alkohola, sajlahko to poveča tveganje za laktacidozo (glejte poglavje “Opozorila in previdnostni ukrepi”).
Food slightly delays and decreases the extent of the absorption of metformin.
Hrana nekoliko upočasni absorpcijo metfomina in zmanjša njen obseg.
Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent LFTs until the abnormality(ies) return(s) to normal.
Bolnikom, pri katerih pride do zvišanja vrednosti aminotransferaz, je treba za potrditev opraviti še drugo preiskavo delovanja jeter, nato pa jih je treba spremljati s pogostimi pregledi jetrnih testov, dokler se nenormalni izvid(i) ne normalizira(jo).
The rate and extent of absorption of metformin from Zomarist 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax (2.0 to 4.0 h).
Hitrost in obseg absorpcije metformina iz zdravila Zomarist 50 mg/1000 mg pa sta bili pri jemanju s hrano zmanjšani, kar se je odražalo na znižanju Cmax za 26 %, zmanjšanju AUC za 7 % in na podaljšanem Tmax (2,0 do 4,0 ure).